Company intelligence / Profile preview

Nephrogen Biotech

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Nephrogen is a biotechnology company focused on developing novel therapeutics for the treatment of chronic and acute kidney diseases. The company's primary research centers on modulating the TGF-beta and BMP-7 signaling pathways to inhibit renal fibrosis and promote tissue regeneration. By targeting the underlying mechanisms of kidney scarring, Nephrogen aims to provide disease-modifying treatments for patients with diabetic nephropathy and other forms of chronic kidney disease. Their current pipeline is in the pre-clinical stage, utilizing small molecule approaches to restore renal function.

Therapeutic areas: Nephrology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Nephrogen Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nephrogen Biotech.

Explore the full profile